REDO study
In the REDO study, we investigated the efficacy of retreatment with ultra-low doses of rituximab (200mg and 500mg) compared with the standard low-dose rituximab (1000mg) for patients with rheumatoid arthritis (RA). Data collection has finished in March 2019.
The REDO study showed that lower doses of rituximab were effective for a large proportion of RA patients. Some participants needed extra medication because of a disease flare. Lower doses of rituximab were associated with less infections. Further research on long-term effectiveness and safety is needed to determine the best strategy to treat RA patients with rituximab.
The results have been published in the Lancet Rheumatology.
The REDO study was sponsored by health care insurers CZ and Menzis.
We work together with 4 other hospitals:
- Radboudumc
- Reade
- Maasstad Ziekenhuis
- Ziekenhuisgroep Twente
Within this project we cooperate with:
- Nadine Boers BSc
- Rogier Thurlings MD PhD
- Frank van den Hoogen MD PhD
- Alfons den Broeder MD PhD
